Discovery of a novel series of selective HCN1 blockers.

Bioorg Med Chem Lett

Johnson & Johnson Pharmaceutical Research & Development, L.L.C., 3210 Merryfield Row, San Diego, CA 92121, United States.

Published: September 2011

The discovery of a series of novel, potent, and selective blockers of the cyclic nucleotide-modulated channel HCN1 is disclosed. Here we report an SAR study around a series of selective blockers of the HCN1 channel. Utilization of a high-throughput VIPR assay led to the identification of a novel series of 2,2-disubstituted indane derivatives, which had moderate selectivity and potency at HCN1. Optimization of this hit led to the identification of the potent, 1,1-disubstituted cyclohexane HCN1 blocker, 2-ethoxy-N-((1-(4-isopropylpiperazin-1-yl)cyclohexyl)methyl)benzamide. The work leading to the discovery of this compound is described herein.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2011.07.051DOI Listing

Publication Analysis

Top Keywords

novel series
8
series selective
8
selective blockers
8
led identification
8
hcn1
5
discovery novel
4
series
4
selective hcn1
4
hcn1 blockers
4
blockers discovery
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!